Mediwound (NASDAQ:MDWD): Oppenheimer Reiterates Buy Rating Today, Has a Target of $14.0000/Share

June 12, 2018 - By Adrian Mccoy

Mediwound (NASDAQ:MDWD) Rating Reaffirmed

Oppenheimer now has a $14.0000 target price on shares of Mediwound (NASDAQ:MDWD). The target price means a potential upside of 107.33 % from the current stock price of Mediwound (NASDAQ:MDWD). This rating was revealed in analysts report on 11 June.

MediWound Ltd. (NASDAQ:MDWD) Ratings Coverage

Among 2 analysts covering MediWound (NASDAQ:MDWD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MediWound has $1400 highest and $8 lowest target. $11’s average target is 62.90% above currents $6.7525 stock price. MediWound had 4 analyst reports since March 20, 2018 according to SRatingsIntel. The stock of MediWound Ltd. (NASDAQ:MDWD) has “Buy” rating given on Thursday, May 10 by Oppenheimer. The stock has “Outperform” rating by Wells Fargo on Tuesday, March 20. The company was maintained on Tuesday, March 20 by Oppenheimer.

The stock increased 1.54% or $0.1025 during the last trading session, reaching $6.7525. About 31,983 shares traded. MediWound Ltd. (NASDAQ:MDWD) has declined 4.32% since June 12, 2017 and is downtrending. It has underperformed by 16.89% the S&P500.

Analysts await MediWound Ltd. (NASDAQ:MDWD) to report earnings on August, 2. They expect $-0.19 EPS, up 5.00 % or $0.01 from last year’s $-0.2 per share. After $-0.17 actual EPS reported by MediWound Ltd. for the previous quarter, Wall Street now forecasts 11.76 % negative EPS growth.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products in Israel. The company has market cap of $182.64 million. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. It currently has negative earnings. The firm also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds.

More notable recent MediWound Ltd. (NASDAQ:MDWD) news were published by: Streetinsider.com which released: “MediWound (MDWD) Granted Marketing Authorization from South Korea’s Ministry of Health for NexoBrid” on June 04, 2018, also Globenewswire.com with their article: “NexoBrid® Receives Marketing Authorization From South Korea’s Ministry of Health” published on June 04, 2018, Streetinsider.com published: “Form 6-K MediWound Ltd. For: Jun 11” on June 11, 2018. More interesting news about MediWound Ltd. (NASDAQ:MDWD) were released by: Streetinsider.com and their article: “MediWound (MDWD) Announces Enrollment Complete in NexoBrid US Phase 3 DETECT Study” published on June 11, 2018 as well as Globenewswire.com‘s news article titled: “MediWound Completes Enrollment in NexoBrid® US Phase 3 DETECT Study” with publication date: June 11, 2018.

MediWound Ltd. (NASDAQ:MDWD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.